Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer

Oncology Nursing Forum

Volumn 41, Issue 1, 2014, Pages 21-29

  Harrington, Joanne M ^a   Schwenke, Dawn C ^a   Epstein, Dana R ^b   Bailey Jr , Donald E ^c  

^a Division of Hematology Oncology   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

Androgen deprivation therapy; Metabolic syndrome; Prostate cancer

Indexed keywords

ANDROGEN; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GONADORELIN; LIPID;

ABDOMINAL OBESITY; ADENOCARCINOMA; AGED; ANDROGEN-DEPRIVATION THERAPY; ARTICLE; BLOOD; BODY COMPOSITION; CHEMICALLY INDUCED DISORDER; COMORBIDITY; COMPARATIVE STUDY; DIET RESTRICTION; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM; NURSING; PHYSIOLOGY; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATE TUMOR;

ANDROGEN-DEPRIVATION THERAPY; METABOLIC SYNDROME; PROSTATE CANCER;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; BLOOD GLUCOSE; BODY COMPOSITION; COMBINED MODALITY THERAPY; COMORBIDITY; DISEASE PROGRESSION; FASTING; GONADOTROPIN-RELEASING HORMONE; HUMANS; INSULIN RESISTANCE; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; OBESITY, ABDOMINAL; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS;

EID: 84893100331     PISSN: 0190535X     EISSN: 15380688     Source Type: Journal    
DOI: 10.1188/14.ONF.21-29     Document Type: Article

References (35)

1. Alberti, K.G., Eckel, R.H., Grundy, S.M., Zimmet, P.Z., Cleeman, J.I., Donato, K.A., Smith, S.C. (2009). Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 120, 1640-1645. doi:10.1161/CIRCULATIONAHA.109.192644
2. Alberti, K.G., Zimmet, P., & Shaw, J. (2005). The metabolic syndrome - A new worldwide definition. Lancet, 366, 1059-1061.
3. Alibhai, S.M., Duong-Hua, M., Sutradhar, R., Fleshner, N.E., Warde, P., Cheung, A.M., & Paszat, L.F. (2009). Impact of androgen deprivation therapy on cardiovascular disease and diabetes. Journal of Clinical Oncology, 27, 3452-3458. doi:10.1200/JCO.2008.20.0923
4. Basaria, S., Lieb, J., Tang, A.M., DeWeese, T., Carducci, M., Eisenberger, M., & Dobs, A.S. (2002). Long-term effects of androgen deprivation therapy in prostate cancer. Clinical Endocrinology, 56, 779-786.
5. Basaria, S., Muller, D.C., Carducci, M.A., Egan, J., & Dobs, A.S. (2006). Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer, 106, 581-587.
6. Braga-Basaria, M., Dobs, A.S., Muller, D.D., Carducci, M.A., John, M., Egan, J., & Basaria, S. (2006). Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. Journal of Clinical Oncology, 24, 3979-3983.
7. Choong, K., & Basaria, S. (2010). Emerging cardiometabolic complications of androgen deprivation therapy. Aging Male, 13, 1-9.
8. Cleffi, S., Neto, A.S., Reis, L.O., Maia, P., Fonseca, F., Wroclawski, M.L., Tobias-Machado, M. (2011). Androgen deprivation therapy and morbid obesity: Do they share cardiovascular risk through metabolic syndrome? Actas Urologicas Espanolas, 35, 259-265.
9. Denis, L.J., & Griffiths, K. (2000). Endocrine treatment in prostate cancer. Seminars in Surgical Oncology, 18, 52-74.
10. Dockery, F., Bulpitt, C.J., Agarwal, S., Donaldson, M., & Rajkumar, C. (2003). Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clinical Science, 104, 195-201.
11. Haffner, S.M. (2006). The metabolic syndrome: Inflammation, diabetes mellitus, and cardiovascular disease. American Journal of Cardiology, 97, 3A-11A. doi:10.1016/j.amjcard.2005.11.010
12. Haidar, A., Yassin, A., Saad, F., & Shabsigh, R. (2007). Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. Aging Male, 10, 189-196.
13. Higano, C. (2012). Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology, 30, 3720-3725. doi:10.1200/JCO.2012.418509
14. Keating, N.L., O'Malley, A.J., & Smith, M.R. (2006). Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology, 24, 4448-4456. doi:10.1200/JCO.2006.06.2497
15. Lage, M.J., Barber, B.L., & Markus, R.A. (2007). Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology, 70, 1104-1108. doi:10.1016/jurology.2007.08.012
16. Lepor, H., & Shore, N.D. (2012). LHRH agonists for the treatment of prostate cancer: 2012. Reviews in Urology, 14, 1-12.
17. Levine, G.N., D'Amico, A.V., Berger, P., Clark, P.E., Eckel, R.H., Keating, N.L., Zakai, N. (2010). Androgen-deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American Heart Association, and American Urological Association: Endorsed by the American Society for Radiation Oncology. CA: A Cancer Journal for Clinicians, 60, 194-201. doi:10.3322/caac.20061
18. Myklak, K., & Wilson, S. (2011). An update on the changing indications for androgen deprivation therapy for prostate cancer. Prostate Cancer, 2011, 1-8. doi:10.1155/2011/419174
19. Ness-Abramof, R., & Apovian, C.M. (2008). Waist circumference measurement in clinical practice. Nutrition in Clinical Practice, 23, 397-404. doi:10.1177/0884533608321700
20. Nobes, J.P., Langley, S.E., & Laing, R.W. (2009). Metabolic syndrome and prostate cancer: A review. Clinical Oncology, 21, 1-9. doi:10.1016/j.clon. 2008.11.013
21. Quon, H., & Loblaw, D.A. (2010). Androgen deprivation therapy for prostate cancer - Review of indications in 2010. Current Oncology, 17(Suppl. 2), S38-S44.
22. Rashid, M.H., & Chaudhary, U.B. (2004). Intermittent androgen deprivation therapy for prostate cancer. Oncologist, 9, 295-301.
23. Saylor, P.J., & Smith, M.R. (2009). Metabolic complications of androgen deprivation therapy for prostate cancer. Journal of Urology, 181, 1998-2008. doi:10.1016.j.juro.2009.01.047
24. Saylor, P.J., & Smith, M.R. (2012). Adverse effects of androgen deprivation therapy: Defining the problem and promoting health among men with prostate cancer. Journal of the National Comprehensive Cancer Network, 8, 211-222.
25. Shahani, S., Braga-Basaria, M., & Basaria, S. (2008). Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. Journal of Clinical Endocrinology and Metabolism, 93, 2042-2049.
26. Shahinian, V.B., Kuo, Y.F., Freeman, J.L., Orihuela, E., & Goodwin, J.S. (2005). Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate cancer. Cancer, 103, 1615-1624.
27. Shuster, A., Patlas, M., Pinthus, J.H., & Mourtzakis, M. (2012). The clinical importance of visceral adiposity: A critical review of methods for visceral adipose tissue analysis. British Journal of Radiology, 85(1009), 1-10. doi:10.1259/bjr/38447238
28. Siegel, R., Naishadham, D., & Jemal, A. (2013). Cancer statistics, 2013. CA: A Cancer Journal for Clinicians, 63, 11-30. doi:10.3322/caac.21166
29. Smith, J.C., Bennett, S., Evans, L.M., Kynaston, H.G., Parmar, M., Mason, M.D., Davies, J.S. (2001). The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. Journal of Endocrinology and Metabolism, 86, 4261-4267.
30. Smith, M.R. (2007). Androgen deprivation therapy for prostate cancer: New concepts and concerns. Current Opinion in Endocrinology, Diabetes, and Obesity, 14, 247-254.
31. Smith, M.R., Finkelstein, J.S., McGovern, F.J., Zietman, A.L., Fallon, M.A., Schoenfeld, D.A., & Kantoff, P.W. (2002). Changes in body composition during androgen deprivation therapy for prostate cancer. Journal of Clinical Endocrinology and Metabolism, 87, 599-603.
32. Smith, M.R., Lee, H., McGovern, F., Fallon, M.A., Goode, M., Zietman, A.L., & Finkelstein, J.S. (2008). Metabolic changes during gonadatropin-releasing hormone agonist therapy for prostate cancer. Cancer, 112, 2188-2194. doi:10.1002/cncr.23440
33. Smith, M.R., Lee, H., & Nathan, D.M. (2006). Insulin sensitivity during combined androgen blockade for prostate cancer. Journal of Clinical Endocrinology and Metabolism, 91, 1305-1308.
34. Trujillo, M.E., & Scherer, P.E. (2005). Adiponectin - Journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. Journal of Internal Medicine, 257, 167-175. doi:10.1111/j.1365-2796.2004.01426.x
35. Yannucci, J., Manola, J., Garnick, M.B., Bhat, G., & Bubley, G.J. (2006). The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. Journal of Urology, 176, 520-525.